FLGT Fulgent Genetics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: FLGT

Price (delayed)

$19.72

Market cap

$560.06M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.39

Enterprise value

$537.14M

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 20

Fulgent Genetics' proprietary technology platform has created a broad, flexible test menu and the ability to continually expand and improve its proprietary genetic reference library while maintaining accessible pricing, high ...

Highlights
Fulgent Genetics's revenue has increased by 10% YoY
The gross profit has grown by 9% YoY but it has contracted by 5% from the previous quarter
The net income has plunged by 81% YoY and by 22% from the previous quarter
FLGT's EPS has dropped by 80% year-on-year and by 21% since the previous quarter
Sector: Healthcare
Industry: Diagnostics & Research
Website: http://fulgentdiagnostics.com
Peers: OBIO OM OPK NEO

Key stats

What are the main financial stats of FLGT

FLGT stock price

How has the Fulgent Genetics stock price performed over time
Intraday
8.71%
1 week
8.11%
1 month
30.42%
1 year
-7.37%
YTD
-24.93%
QTD
24.03%

Financial performance

How have Fulgent Genetics's revenue and profit performed over time
Revenue
$320.35M
Gross profit
$124.02M
Operating income
-$105.92M
Net income
-$73.81M
Gross margin
38.7%
Net margin
-23%
The net income has plunged by 81% YoY and by 22% from the previous quarter
Fulgent Genetics's net margin has plunged by 65% YoY and by 22% from the previous quarter
Fulgent Genetics's operating income has decreased by 47% YoY and by 16% from the previous quarter
Fulgent Genetics's operating margin has decreased by 35% YoY and by 17% from the previous quarter

Price vs fundamentals

How does FLGT's price correlate with its fundamentals

Growth

What is Fulgent Genetics's growth rate over time

Valuation

What is Fulgent Genetics stock price valuation
FLGT P/E details
P/E
N/A
P/B
0.59
P/S
1.9
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.68
FLGT's EPS has dropped by 80% year-on-year and by 21% since the previous quarter
The price to book (P/B) is 46% lower than the 5-year quarterly average of 1.0 and 10% lower than the last 4 quarters average of 0.6
The company's equity fell by 7% YoY and by 6% QoQ
FLGT's P/S is 24% below its 5-year quarterly average of 2.3 and 17% below its last 4 quarters average of 2.1
Fulgent Genetics's revenue has increased by 10% YoY

Efficiency

How efficient is Fulgent Genetics business performance
The company's return on assets has shrunk by 88% YoY and by 24% QoQ
The return on equity has dropped by 86% year-on-year and by 24% since the previous quarter
The company's return on invested capital has shrunk by 75% YoY and by 21% QoQ
FLGT's ROS has dropped by 55% year-on-year and by 22% since the previous quarter

Dividends

What is FLGT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for FLGT.

Financial health

How did Fulgent Genetics financials performed over time
FLGT's quick ratio is down by 36% year-on-year and by 23% since the previous quarter
Fulgent Genetics's total liabilities has increased by 35% YoY and by 5% from the previous quarter
Fulgent Genetics's debt is 100% less than its equity
The company's equity fell by 7% YoY and by 6% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.